Takeda Pharmaceutical (TAK) Change in Cash (2018 - 2026)

Takeda Pharmaceutical has reported Change in Cash for 9 years, with the latest figure at -$881.0 million in Q2 2026.

• On a quarterly basis, Change in Cash fell 290.2% year-over-year to -$881.0 million in Q2 2026; TTM through Jun 2026 was $541.4 million, a 188.19% increase from a year earlier, with the FY2026 full-year figure at $1.1 billion, up 378.02% from the prior year.
• Change in Cash was -$881.0 million for Q2 2026 at Takeda Pharmaceutical, down from $1.2 billion in the prior quarter.
• The five-year high for Change in Cash was $4.9 billion in Q3 2022, with the low at -$2.7 billion in Q1 2022.
• Average Change in Cash over 5 years is $190.9 million, with a median of -$62.7 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Change in Cash jumped 280.45% in 2022, then slumped 674.31% in 2025.
• Over 5 years, Change in Cash stood at $173.7 million in 2022, then jumped by 272.15% to $646.5 million in 2023, then slumped by 492.6% to -$2.5 billion in 2024, then advanced by 25.58% to -$1.9 billion in 2025, then surged by 53.36% to -$881.0 million in 2026.
• The last three Change in Cash figures came in at -$881.0 million (Q2 2026), $1.2 billion (Q1 2026), and -$1.9 billion (Q4 2025), per Business Quant data.